Evaluation of photodynamic ther- apy for the treatment of exudative age-related macular degeneration (ARMD) with subfoveal neovascularization

10-13-2004 | 

AETMIS's assessment is based on a rigorous examination of the existing scientific data. According to this assessment, the efficacy of photodynamic therapy with verteporfin photosensitizer is well established for two forms of ARMD: 1) exudative subfoveal ARMD with predominantly classic neovascularization, and 2) exudative subfoveal ARMD with pure occult neovascularization. AETMIS also concludes that, given the potentially rapid progression of neovascular ARMD, its early detection could help reduce severe, irreversible vision loss and consequently major expenses, by the public system, for managing this disease and its sequelae.

The report proposes several options for detecting the disease earlier. The optimal implementation of this technology will, however, require major changes to the organization of the care and services in the area of ocular health. Lastly, AETMIS presents various recommendations that urge ministerial and professional authorities to recognize ARMD as a major public health problem and to encourage initiatives for the population-based management of ARMD in the broader context of managing preventable blindness.

 

REF56

Subscribe to our newsletter now

Subscription